CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $198.93M, lower than 95% of all stocks globally
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
198.93MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
-0.1790xvs all stocks
52-Week Change
119.99%vs all stocks
Market Capitalization
198.93MUSDvs all stocks (USD)
Enterprise Value
185.83MUSDvs all stocks (USD)
Forward P/E
-8.90xvs Biotechnology peers
Enterprise to EBITDA
-6.67xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-27.47%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 19, 2026Gross Profit (TTM)
-9.65MUSDvs all stocks (USD)
EBITDA (TTM)
-27.87MUSDvs all stocks (USD)
Net Income (TTM)
-415.07MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-14.87MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-5.55MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-15.10MUSDvs all stocks (USD)
Pre-tax Income
-293.42MUSDFY2025 · Dec 31, 2025Net Income
-293.42MUSDFY2025 · Dec 31, 2025EBIT
-293.42MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-294.31MUSDFY2025 · Dec 31, 2025Research & Development
5.76MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
9.34MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
0.00USDFY2025 · Dec 31, 2025EPS (Basic)
-34.67USDFY2025 · Dec 31, 2025EPS (Diluted)
-34.67USDFY2025 · Dec 31, 2025Basic Shares Outstanding
8.46MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
8.46MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-293.42MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-293.15MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
82.40MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-293.42MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
5.44KUSDFY2025 · Dec 31, 2025Stock-based Compensation
1.33MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-1.06MUSDFY2025 · Dec 31, 2025Other Financing Charges
-5.55MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
74.45MUSDFY2025 · Dec 31, 2025Shares Outstanding
43.84MSharesUpdated Jul 19, 2026Float Shares
30.87MSharesUpdated Jul 19, 2026Shares Short
1.90MSharesUpdated Jul 19, 2026Short Ratio
5.59daysvs all stocks
Short % of Shares Outstanding
4.28%vs all stocks
% Held by Insiders
3.34%vs all stocks
% Held by Institutions
97.40%vs all stocks
Total Cash (MRQ)
78.06MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.68USDUpdated Jul 19, 2026Total Debt (MRQ)
60.00MUSDvs all stocks (USD)
Current Ratio (MRQ)
17.65xvs Biotechnology peers
Book Value per Share (MRQ)
-5.79USDUpdated Jul 19, 2026Total Assets
97.97MUSDvs all stocks (USD)
Total Current Assets
83.10MUSDFY2025 · Dec 31, 2025Total Liabilities
238.72MUSDFY2025 · Dec 31, 2025Total Non-current Assets
14.87MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
236.43MUSDFY2025 · Dec 31, 2025Total Current Liabilities
2.29MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
82.30MUSDFY2025 · Dec 31, 2025Accounts Payable
639.71KUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
60.00MUSDFY2025 · Dec 31, 2025Common Stock (Book)
4.33KUSDFY2025 · Dec 31, 2025Retained Earnings
-688.80MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
-140.75MUSDvs all stocks (USD)
52-Week Low
1.76USDUpdated Jul 19, 202652-Week High
12.46USDUpdated Jul 19, 202652-Week Change
119.99%vs all stocks
Beta
-0.1790xvs all stocks
50-Day MA
4.87USDUpdated Jul 19, 2026200-Day MA
4.90USDUpdated Jul 19, 2026Avg 10-Day Volume
187.93KSharesUpdated Jul 19, 2026Avg 30-Day Volume
301.37KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-37.03USDUpdated Jul 19, 2026Other Income / Expense
-275.22MUSDFY2025 · Dec 31, 20253 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
Liquidity Ratios Elevated
It can cover near-term bills from cash alone, not just from inventory.
Reads
Where is this company structurally exposed?
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $198.93M, lower than 95% of all stocks globallySignificant
Market cap (USD): 198,933,787Global P5: 269,387,740.27
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
ImmuneOncia Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Sillajen Inc.
Tier 1ProductionApproval-Gated PipelineRule
Humedix Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
RxSight Inc.
Tier 1ProductionApproval-Gated PipelineRule
TaiGen Biopharmaceuticals Holdings Limited
Tier 1ProductionApproval-Gated PipelineRuleRisk
NextBioMedical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Genomictree Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
LENZ Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Camp4 Therapeutics Corp.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Onward Medical
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Ourpalm Co. Ltd.
3 interpretationsPartial Recovery After Sharp DeclineCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios Elevated
Silver Tiger Metals Inc.
3 interpretationsPartial Recovery After Sharp DeclineCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios Elevated
GoldQuest Mining Corp.
3 interpretationsPartial Recovery After Sharp DeclineCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios Elevated